Journal
EPIGENOMICS
Volume 11, Issue 1, Pages 81-93Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2018-0121
Keywords
blood DNA methylation; epigenetic modification; epigenome-wide association study; risk biomarker; triple-negative breast cancer
Categories
Funding
- DKFZ
- German Federal Ministry of Education and Research (BMBF) [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114, 01DN15021]
- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Robert Bosch Foundation, Stuttgart
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance
- Institute of the Ruhr University Bochum (IPA), Bochum
- Department of Internal Medicine
- Evangelische Kliniken Bonn gGmbH
- Johanniter Krankenhaus, Bonn, Germany
- Deutsche Forschungsgemeinschaft
- Ruprecht-Karls-Universitat Heidelberg
Ask authors/readers for more resources
Aim: To identify DNA methylation biomarkers in peripheral blood samples from triple-negative breast cancer (TNBC) patients. Materials & methods: We conducted an epigenome-wide association study (EWAS): the most promising markers were identified in 233 TNBC case-control pairs (discovery set) and subsequently validated in an independent validation set (57 TNBC patients and 124 controls). Results: cg06588802 (LINC00299/ID2) showed a higher methylation in TNBC patients compared with controls (discovery set: 3% increase, p-value = 0.0009; validation set: 2% increase, p-value = 0.01). Consistent results at four neighboring methylation probes and the strong negative correlation (rho = -0.93) with LINC00299 expression add plausibility to this result. Conclusion: Hypermethylation of LINC00299 in peripheral blood may constitute a useful circulating biomarker for TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
